Illumina (ILMN) Set to Announce Earnings on Thursday

Illumina (NASDAQ:ILMN) is scheduled to be announcing its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm posted $0.14 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts expect Illumina to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $123.05 on Wednesday. The company’s fifty day moving average price is $130.80 and its 200 day moving average price is $127.15. Illumina has a 1 year low of $89.00 and a 1 year high of $213.91. The company has a market capitalization of $19.60 billion, a PE ratio of -16.76 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. Barclays upped their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $167.70.

Insider Buying and Selling

In other news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is owned by company insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.